Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

LBBAP Versus ILR in Patients With New-Onset LBBB and Moderately Reduced LVEF After TAVI (LBB(AP)TAVI)

13 de noviembre de 2026 actualizado por: University Hospital, Clermont-Ferrand

Comparison of Left Bundle Branch Area Pacing (LBB(AP)) and Implantable Loop Recorder (ILR) in Patients With New-onset Left Bundle Branch Block and Moderately Reduced LVEF After Transcatheter Aortic Valve Implantation (TAVI): A Randomized Multicenter Study.

Patients with new-onset complete LBBB (QRS > 120 ms, persisting > 24 h after TAVI) and moderately reduced LVEF (35-50%) will be screened in participating centers.

Eligible patients will be centrally randomized 1:1 (stratified by center and atrial fibrillation (yes/no)) to either:

  • Experimental arm: Left bundle branch area pacing (LBB(AP)) with Biotronik pacemaker and dedicated conduction system pacing leads.
  • Control arm: Implantable loop recorder (ILR, Biotronik BIOMONITOR IV) for rhythm monitoring.

The occurrence of the following events within 12 months of randomization will be evaluated: hospitalization for heart failure, syncope or hemodynamically significant dizziness, or high-grade atrioventricular conduction disturbance.

The impact of LBB(AP) compared to ILR monitoring will be evaluated at 6, 12, 24, and 36 months regarding: incidence of atrial fibrillation; incidence of non-sustained ventricular tachycardia; evolution of left ventricular ejection fraction; quality of life; hospitalizations; mortality; medico-economic outcomes; qccurrence of high-grade AV conduction disorders beyond 12 months; omplications related to pacemaker or ILR implantation; unscheduled pacemaker implantation in the ILR group.

Patients will be monitored following a regular schedule that includes clinical visits, transthoracic echocardiography , ECG, remote device monitoring, and EQ-5D at 6, 12, 24 and 36 months.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

700

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Angers, Francia, 49000
        • CHU d'Angers
        • Investigador principal:
          • Antoine POIRIER
      • Clermont-Ferrand, Francia, 63000
      • Dijon, Francia, 21000
        • CHU de DIJON
        • Investigador principal:
          • Fabien GARNIER

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Patients with new-onset complete left bundle branch block (LBBB) defined as QRS duration >120 ms, occurring after TAVI and persisting for >24 hours on ECG. New-onset complete LBBB will be confirmed by QRS duration >120 ms together with standard morphological criteria (broad, notched or slurred R waves in leads I, aVL, V5 and V6, with absence of Q waves in V5-V6), assessed by the site cardiologist and confirmed by the adjudication committee, in line with current ESC and ACC/AHA/HRS recommendations.
  2. Left ventricular ejection fraction (LVEF) between 35% and 50%, assessed within one month before TAVI, in a stable hemodynamic state.
  3. Patients implanted with a self-expanding or balloon-expandable valve.
  4. Age ≥ 18 years.
  5. TAVI procedure performed according to current ESC guidelines. The applicable reference is the 2025 ESC/EACTS Guidelines for the management of valvular heart disease (Praz, et al. Eur Heart J. (2025) 46, 4635-4736), or any subsequent official ESC update in force at the time of each patient's procedure.
  6. Life expectancy > 1 year.
  7. Affiliation to a social security scheme
  8. Written informed consent provided before study enrollment.

Exclusion Criteria:

  1. Permanent pacemaker implantation (PPI) before TAVI.
  2. Complete atrioventricular block after TAVI leading to immediate PPI.
  3. Permanent pacemaker implantation after TAVI for another indication (non-protocol).
  4. Pre-existing LBBB before TAVI.
  5. Trans-venous permanent pacemaker implantation: No superior vena cava access or mechanical tricuspid valve.
  6. Pregnancy or breastfeeding.
  7. No affiliation to a social security scheme.
  8. Refusal to participate or withdrawal of informed consent.
  9. Incapacity to consent.
  10. Adults under legal protection (trusteeship, guardianship, curatorship).

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Left bundle branch area pacing with pacemaker and conduction system pacing (AMVIA SKY DR-T device)

LBB(AP) procedure will be performed by experienced operators according international guidelines and expert consensus. The implantation technique will be those used routinely in these expert centers.

The procedure will begin with a vein access (axillary, sub-clavian or cephalic). The atrial, if necessary, will be implanted as usual practice. LBB(AP) lead will be implanted as recommended. LBB(AP) positioning criteria, as described in reference clinical studies, will be checked in order to differentiate between LBB(AP) and deep septal pacing.

Otro: Implantable loop recorder for rhythm monitoring (ILR, Biotronik BIOMONITOR IV Device)

Control arm

ILR Procedure will be performed by experienced operators according international guidelines and expert consensus. The implantation technique will be those used routinely in these expert centers.

The implanted device will be a Biomonitor IV (Biotronik, Berlin, Germany) and next generation if necessary.

The implantable Loop Recorder is a single-lead ECG monitor of small size with long-term functionality (approximately 3 to 5 years). It is implanted under local anesthesia in the subcutaneous space of the left thoracic region (incision at the level of the 4th left intercostal space at a 45° angle).

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
The first occurrence of one of the following events : hospitalization for worsening heart failure, episode of syncope or dizziness, high-grade atrioventricular conduction disturbance)
Periodo de tiempo: From randomization to 12 follow up

The primary efficacy endpoint is a composite clinical outcome evaluated at 12 months after randomization, defined as the first occurrence of one of the following events:

  1. Hospitalization for worsening heart failure,
  2. Episode of syncope or dizziness,
  3. High-grade atrioventricular conduction disturbance (second-degree AV block type II or third-degree AV block requiring implantation of a permanent pacemaker, documented > 3 seconds on ILR or ECG)).

The composite endpoint will be analyzed as time-to-event data with death considered as a competing risk.

From randomization to 12 follow up

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Incidence of atrial fibrillation, ventricular tachycardia, non-sustained ventricular tachycardia
Periodo de tiempo: At 6,12, 24 and 36 months after randomization
At 6,12, 24 and 36 months after randomization
Evolution of LVEF
Periodo de tiempo: At 6,12, 24 and 36 months after randomization

Measurement of LVEF at inclusion and at each follow-up time point. The change in LVEF over time will be assessed relative to the date of inclusion and the preceding time point.

At 6,12, 24 and 36 months after randomization
Evolution of Quality of life (EQ-5D)
Periodo de tiempo: At 6, 12, 24 and 36 months after randomization

Measurement of EQ-5D at inclusion and at each follow-up time point. The change in EQ-5D over time will be assessed relative to the date of inclusion and the preceding time point.

At 6, 12, 24 and 36 months after randomization
Incidence of Hospitalizations (all-cause, cardiovascular, HF-related)
Periodo de tiempo: At 6, 12, 24 and 36 months after randomization
At 6, 12, 24 and 36 months after randomization
Incidence of Mortality (all-cause, cardiovascular, HF-related)
Periodo de tiempo: At 6, 12, 24 and 36 months after randomization

Measurement of the cumulative incidence of all-cause, cardiovascular, and heart failure-related mortality at 6, 12, 24, and 36 months after randomization, based on the occurrence and documented cause of death.

At 6, 12, 24 and 36 months after randomization
Medico-economic evaluation
Periodo de tiempo: At 6, 12, 24 and 36 months after randomization
At 6, 12, 24 and 36 months after randomization
Complications related to pacemaker or ILR implantation
Periodo de tiempo: At 6, 12, 24 and 36 months after randomization
At 6, 12, 24 and 36 months after randomization
Unscheduled pacemaker implantation in the ILR group
Periodo de tiempo: At 6, 12, 24 and 36 months after randomization
At 6, 12, 24 and 36 months after randomization

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

15 de octubre de 2026

Finalización primaria (Estimado)

15 de octubre de 2033

Finalización del estudio (Estimado)

15 de octubre de 2034

Fechas de registro del estudio

Enviado por primera vez

6 de octubre de 2026

Primero enviado que cumplió con los criterios de control de calidad

26 de octubre de 2026

Publicado por primera vez (Actual)

2 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

13 de noviembre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir